Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab in Macular Edema Associated With CRVO
NCT02091505Unknown
- Sponsor
- Mie University
- Start
- Dec 2013
- Primary completion
- May 2016
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of ranibizumab in macular edema, sponsored by Mie University. Primary endpoint: Best-corrected visual acuity at 12 months. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT02091505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02091505.